1. Amery, W., and Gough, D.A., 1981, Levamisole and immunotherapy: some theoretic and practical considerations and their relevance to human disease, Oncology, 38: 168.
2. Ludwig Cancer Study Group., 1978, Search for the possible role of “immunotherapy” in operable bronchial non-small cell carcinoma (stage I and II): A phase I study with Corynebacterium parvum intrapleurally, Cancer Immunol. Immunother., 4: 69.
3. Rosso, R., Nobile, M.T., Brema, F., Porcile, G., Cinquegrana, A., De Palma, M., and Rubagotti, A., 1982, Randomized trial of chemoimmunotherapy in advanced nonoat-cell lung cancer, Tumori, 68: 527.
4. Gutterman, J.U., Mavligit, G.M., and Hersh E.M., 1976, Chemoimmunotherapy of human solid tumors, Med. Clin. North Amer., 60: 441.
5. Dimitrov, N.V., Conray, J., Suhrland, L.G., Singh, T., and Teitlebaum, H., 1978, Combination therapy with Corynebacterium parvum and doxorubicin hydrochloride in patients with lung cancer, in: “Immunotherapy of Cancer: Present Status of Trial in Man”, W.D. Terry, and D. Windhorst, eds., Raven Press, New York, 181.